Resultados CaixaImpulse 2025
Resultados CaixaImpulse 2025
CAIXAIMPULSE 2025 CALL |
|
|---|---|
Total budget |
€ 3.932.699,16 |
Number of proposals submitted |
428 |
Number of eligible proposals |
428 |
Number of projects pre-selected |
64* |
Number of projects selected |
29* |
Success rate |
6,7 % |
Table 1: General information of the CaixaImpulse Health Innovation Call 2025.
*These numbers do not include the additional projects currently in the programme that have applied to move on to higher stages by means of an Evaluation checkpoint.
Figure 1. Number of projects selected by territory and project stage.
PROJECT PHASE |
PROPOSALS SUBMITTED |
PROJECTS PRE-SELECTED |
PROJECTS SELECTED |
||
|---|---|---|---|---|---|
Stage 1 |
248 |
30 |
12,1 % |
17 |
6,9 % |
Stage 2 |
162 |
26 |
16 % |
10 |
6,2 % |
Stage 3 |
18 |
8 |
44,4 % |
2 |
11,1 % |
428 |
64 |
15 % |
29 |
6,8 % |
|
Table 2. Success rate by project stage
PROJECT PHASE |
APPLICATIONS FROM INTERNAL EVALUATION CHECKPOINT |
PROJECTS SELECTED |
|
|---|---|---|---|
Stage 2 |
4 |
1 |
25 % |
Stage 3 |
4 |
1 |
25 % |
Table 3. Success rate by project stage (Applications currently in the programme, undergoing internal checkpoint evaluation to progress to higher stages).
PROJECT PHASE |
THERAPEUTIC |
MEDICAL TECHNOLOGY AND DIGITAL HEALTH |
TOTALS |
|---|---|---|---|
Stage 1 |
8 |
9 |
17 |
Stage 2 |
5 |
6 |
11 |
Stage 3 |
1 |
2 |
3 |
14 |
17 |
31 |
Table 4. Number of projects selected by business area and project stage.
PROJECT LEADER |
PROPOSALS SUBMITTED |
PROJECTS PRE-SELECTED |
PROJECTS SELECTED* |
SUCCESS RATE* |
|---|---|---|---|---|
Women |
212 |
29 |
14 |
6,6 % |
Men |
213 |
33 |
14 |
6,5 % |
Others |
1 |
0 |
0 |
|
Prefer not to say |
2 |
2 |
1 |
|
428 |
29 |
Table 5: Success rate by gender.
*These data include only the proposals from the 2025 Call. Of the projects progressing from previous stages, 2 are led by women.
Resultados CaixaImpulse 2024
Resultados CaixaImpulse 2024
CaixaImpulse 2024 information |
|
|---|---|
Total budget |
3.381.759 € |
Number of proposals submitted |
413 |
Number of eligible proposals |
406 |
Number of projects pre-selected |
72 |
Number of projects selected |
29 |
Success rate |
7 % |
Table 1. General information of the CaixaImpulse Health Innovation Call 2024
Figure 1. Number of projects selected by territory and project stage
PROJECT STAGE |
PROPOSALS SUBMITTED |
PROJECTS PRE-SELECTED |
PROJECTS SELECTED |
||
|---|---|---|---|---|---|
Stage 1 |
224 |
30 |
13,4 % |
16 |
7,1 % |
Stage 2 |
166 |
30 |
18 % |
11 |
6,6 % |
Stage 3 |
23 |
12 |
52,2 % |
2 |
8,7 % |
|
413 |
72 |
17 % |
29 |
7 % |
Table 2. Success rate by project stage
PROJECT STAGE |
THERAPEUTIC |
MEDICAL TECHNOLOGY |
TOTAL |
|---|---|---|---|
Stage 1 |
6 |
10 |
16 |
Stage 2 |
5 |
6 |
11 |
Stage 3 |
1 |
1 |
2 |
|
12 |
17 |
29 |
Table 3. Number of projects selected by business area and project stage
PROJECT LEADER |
PROPOSALS SUBMITTED |
PROJECTS PRE-SELECTED |
PROJECTS SELECTED |
|---|---|---|---|
Women |
188 |
33 |
7 |
Men |
219 |
38 |
21 |
Others |
1 |
0 |
0 |
Prefer not to say |
5 |
1 |
1 |
Table 4. Results by gender
Resultados CaixaImpulse 2023
Resultados CaixaImpulse 2023
CaixaImpulse 2023 information |
|
|---|---|
Total budget |
3.321.911 € |
Number of proposals submitted |
318 |
Number of eligible proposals |
315 |
Number of projects pre-selected |
70 |
Number of projects selected |
29 |
Success rate |
9,1 % |
Table 1. General information of the CaixaImpulse Health Innovation Call 2023
Figure 1. Number of proposals submitted by territory
Figure 2. Number of projects selected by territory
Project phase |
Proposals submitted |
Projects pre-selected |
Projects selected |
||
|---|---|---|---|---|---|
Phase 1 |
188 |
30 |
16 % |
15 |
8 % |
Phase 2 |
108 |
30 |
28 % |
12 |
11 % |
Phase 3 |
22 |
10 |
45 % |
2 |
9 % |
|
318 |
70 |
22 % |
29 |
9 % |
Table 2. Success rate by project phase
Project phase |
Therapeutic |
Medical technology |
Total |
|---|---|---|---|
Phase 1 |
6 |
9 |
15 |
Phase 2 |
6 |
6 |
12 |
Phase 3 |
1 |
1 |
2 |
|
13 |
16 |
29 |
Table 3. Number of projects selected by thematic area and project phase
Project leader |
Proposals submitted |
Projects preselected |
Projects selected |
||
|---|---|---|---|---|---|
Women |
156 |
38 |
24 % |
16 |
10 % |
Men |
162 |
32 |
20 % |
13 |
8 % |
|
318 |
70 |
22 % |
29 |
9 % |
Table 4. Results by gender
Projetos selecionados CaixaImpulse 2025
Projetos selecionados CaixaImpulse 2025
CODE |
TITLE |
PROJECT LEADER |
CENTRE |
MODALITY |
PARTNER INSTITUTIONS |
STAGE |
BUSINESS AREA |
BUDGET (€) |
|---|---|---|---|---|---|---|---|---|
CI25-10137 |
Design and Fabrication of Drug-Eluting Biodegradable Polycaprolactone mesh implants |
Maria Elisabete Teixeira da Silva |
Institute of Science and Innovation in Mechanical and Industrial Engineering (INEGI) |
Consortium |
Universidade do Porto |
STAGE 1 |
Medical Devices |
49.924,56 |
CI25-10210 |
Pedro Morais |
2Ai - Applied Artificial Intelligence Laboratory Instituto Politécnico do Cávado e do Ave |
Individual |
N/A |
STAGE 1 |
Digital Health |
50.000,00 |
|
CI25-10249 |
Next-Generation Antimicrobials: A Precision Medicine Approach to Gram-Negative Infections |
Marc Torrent |
Universitat Autònoma de Barcelona (UAB) |
Individual |
N/A |
STAGE 1 |
Therapeutics |
49.000,00 |
CI25-10265 |
Advanced Gamma Detectors for Precision Medicine and Theranostics |
Pedro Correia |
University of Aveiro |
Individual |
N/A |
STAGE 1 |
Medical Devices |
50.000,00 |
CI25-10269 |
Boosting spine REGENeration with customized fetal matrIX ingredients |
Joana Caldeira |
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação |
Individual |
N/A |
STAGE 1 |
Therapeutics |
50.000,00 |
CI25-10325 |
Marta R. Casanova |
Universidade do Minho |
Individual |
N/A |
STAGE 1 |
Diagnostics |
49.939,60 |
|
CI25-10354 |
Blood-brain barrier-on-a-chip (BBB-oC) for drug testing of brain-targeting delivery |
Anna Lagunas |
Fundació Institut de Bioenginyeria de Catalunya |
Individual |
N/A |
STAGE 1 |
Diagnostics |
50.000,00 |
CI25-10370 |
MicroAspiration Retrieval System - A novel thrombectomy device for distal vessel occlusion strokes |
Marc Ribó |
Fundació Hospital Universitari Vall d´Hebron - Institut de Recerca (VHIR) |
Individual |
N/A |
STAGE 1 |
Medical Devices |
49.000,00 |
CI25-10420 |
Monitoring Chamber based on Cherenkov for FLASH beam monitoring and control |
Pedro Assis |
Laboratório de Instrumentação e Física Experimental de Partículas |
Individual |
N/A |
STAGE 1 |
Medical Devices |
50.000,00 |
CI25-10446 |
Preclinical development of a first-in-class treatment for autism spectrum disorder |
Mercè Pallàs |
Universitat de Barcelona |
Consortium |
Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P. |
STAGE 1 |
Therapeutics |
50.000,00 |
CI25-10447 |
CUstom-MAde DEvice design for Complex Structural Heart Diseases |
Dabit Arzamendi |
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Individual |
N/A |
STAGE 1 |
Medical Devices |
50.000,00 |
CI25-10473 |
AI-Powered Screening of R-loop Modulators for Cancer Therapy |
Robert Martin |
Fundação GIMM - Gulbenkian Institute for Molecular Medicine |
Individual |
N/A |
STAGE 1 |
Therapeutics |
50.000,00 |
CI25-10539 |
Harness lncRNA targeting to enhance treatment for colorectal cancer |
Luisa Statello |
Fundación para la Investigación Médica Aplicada (FIMA/CIMA) |
Individual |
N/A |
STAGE 1 |
Therapeutics |
50.000,00 |
CI25-10647 |
A Nanovaccine-Based Immunotherapy Targeting Klebsiella pneumoniae Colonization |
Astrid Pérez |
Instituto de Salud Carlos III |
Individual |
N/A |
STAGE 1 |
Therapeutics |
49.000,00 |
CI25-10655 |
Generating Artificial Targets to Deliver Therapies Selectively to the Brain |
Daniel González |
Fundació Institut de Bioenginyeria de Catalunya |
Individual |
N/A |
STAGE 1 |
Therapeutics |
50.000,00 |
CI25-10683 |
Combining the power of surgery and light in the treatment of cancer |
Ana Piqueras Hinojo |
Fundació Institut d’Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) |
Individual |
N/A |
STAGE 1 |
Medical Devices |
50.000,00 |
CI25-10749 |
LINE-1 Identification for novel elements with active retrotransposition |
Marc Güell |
Universitat Pompeu Fabra (UPF) |
Individual |
N/A |
STAGE 1 |
Therapeutics |
49.000,00 |
CI25-20009 |
Anna Roig |
Institut de Ciència de Materials de Barcelona (ICMAB) |
Individual |
N/A |
STAGE 2 |
Medical Devices |
150.000,00 |
|
CI25-20024 |
Automating Preoperative Assessments for Enhanced Patient Care and Healthcare Efficiency |
Ancor Serrano |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Individual |
N/A |
STAGE 2 |
Medical Devices |
149.482,89 |
CI25-20156 |
A TDP-43 sensor for the diagnosis of neurodegenerative diseases |
María del Valle Palomo |
Fundación IMDEA Nanociencia |
Consortium |
Fundación para la Investigación Biomédica del Hospital Clínico San Carlos |
STAGE 2 |
Diagnostics |
150.000,00 |
CI25-20197 |
Validation of a novel epigenetic decoding of blood DNA to predict clinical benefit of immunotherapy |
Isabel Barragán |
Fundación para la Investigación de Málaga en Biomedicina y Salud |
Individual |
N/A |
STAGE 2 |
Diagnostics |
145.200,00 |
CI25-20385 |
Non-Invasive Prediction of the Benefit of Immunotherapy in Advanced Lung Cancer |
Mónica Martínez-Fernández |
Instituto de Investigación Sanitaria Galicia Sur (IISGS) |
Individual |
N/A |
STAGE 2 |
Medical Devices |
150.000,00 |
CI25-20397 |
TAR-NK: A TGF-β- and Activin A-Resistant off-the-shelf NK cell product for cancer treatment |
Aura Muntasell |
Hospital del Mar Research Institute (HMRIB) |
Individual |
N/A |
STAGE 2 |
Therapeutics |
144.100,00 |
CI25-20532 |
4D bioresorbable stent: a lifelong solution for pediatric aortic coarctation |
Andrés García |
IQS School Of Engineering, Universitat Ramon Llull |
Consortium |
Universitat Politècnica de Catalunya (UPC) |
STAGE 2 |
Medical Devices |
148.500,00 |
CI25-20596 |
Engineering a technology for site-specific transgene delivery in tumors using tumor-specific T cells |
Alba Rodriguez |
Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer |
Individual |
N/A |
STAGE 2 |
Therapeutics |
149.952,00 |
CI25-20598 |
Joan Seoane |
Fundació privada Institut Investigació Oncologica Vall Hebron (VHIO) |
Individual |
N/A |
STAGE 2 |
Therapeutics |
150.000,00 |
|
CI25-20711 |
Accelerating an armored CAR T cell therapy for metastatic/refractory bone and soft tissue sarcoma |
Clara Bueno |
Institut de Recerca Contra la Leucèmia Josep Carreras |
Consortium |
Fundació Privada per a la Recerca i la Docència Sant Joan de Déu |
STAGE 2 |
Therapeutics |
149.600,00 |
CI25-2U079 |
Overcoming resistance to virotherapy for pediatric brain tumors |
Marta M Alonso |
Fundación para la Investigación Médica Aplicada (Cima Universidad de Navarra) |
Individual |
N/A |
STAGE 2 |
Therapeutics |
150.000,00 |
CI25-30194 |
Óscar Pérez |
Fundación Centro Tecnolóxico de Telecomunicacións de Galicia (GRADIANT) |
Consortium |
Fundación Pública Galega de Investigación Biomédica Galicia Sur |
STAGE 3 |
Medical Devices |
500.000,00 |
|
CI25-30479 |
TREX2 inhibitors: a breakthrough keratinocyte-based therapy for Psoriasis and beyond |
Sara Preciado |
Institut d´Investigació Biomèdica de Bellvitge (IDIBELL) |
Individual |
N/A |
STAGE 3 |
Therapeutics |
499.999,50 |
CI25-3U559 |
Pilar Coy |
Universidad de Murcia |
Individual |
N/A |
STAGE 3 |
Medical Devices |
500.000,00 |
Projetos selecionados CaixaImpulse 2024
Projetos selecionados CaixaImpulse 2024
CODE |
TITLE |
PROJECT LEADER |
CENTRE |
MODALITY |
PARTNER INSTITUTIONS |
STAGE |
BUSINESS AREA |
BUDGET (€) |
|---|---|---|---|---|---|---|---|---|
CI24-10034 |
Improving taxol response through the manipulation of the cancer tubulin code |
Sonia Silva |
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação |
Consortium |
Universidade do Porto |
STAGE 1 |
Therapeutics |
49,967,00 |
CI24-10180 |
Molecular glue degraders for a novel drug target in acute myeloid leukemia |
Marcus Buschbeck |
Fundació Institut de Recerca Contra la Leucèmia Josep Carreras |
Individual |
N/A |
STAGE 1 |
Therapeutics |
49,000,00 |
CI24-10227 |
Generating tissue resident memory T cells for cancer immunotherapy |
Marc Veldhoen |
Instituto de Medicina Molecular |
Individual |
N/A |
STAGE 1 |
Therapeutics |
50,000,00 |
CI24-10473 |
Chemical inhibition of novel Diffuse Midline Glioma vulnerabilities |
Luciano Di Croce |
Fundació Centre de Regulació Genòmica (CRG) |
Individual |
N/A |
STAGE 1 |
Therapeutics |
50,000,00 |
CI24-10612 |
Manuel Portero |
Institut De Recerca Biomedica De Lleida. Fundació Dr. Pifarre |
Individual |
N/A |
STAGE 1 |
Therapeutics |
41,000,00 |
|
CI24-10630 |
Non-opioid light-activated drugs for pain management without side effects |
Amadeu Llebaria |
Consejo Superior de Investigaciones Científicas (CSIC) |
Consortium |
Institut de Génomique Fonctionnelle (France); University of Montpellier (France) |
STAGE 1 |
Therapeutics |
50,000,00 |
CI24-10110 |
Genetic predisposition to myocardial infarction in the young |
Ramon Brugada |
Institut d'Investigació Biomèdica de Girona (IDIBGI) |
Individual |
N/A |
STAGE 1 |
Diagnostics |
49,000,00 |
CI24-10322 |
CELLECTED - An Innovative Approach for Non-Invasive Bladder Cancer Detection and Patient Monitoring |
Raphaël Canadas |
Universidade do Porto |
Individual |
N/A |
STAGE 1 |
Diagnostics |
49,999,00 |
CI24-10486 |
Pablo Naval |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Individual |
N/A |
STAGE 1 |
Medical Devices |
50,000,00 |
|
CI24-10491 |
An aptamer-based rapid diagnostic test for the simultaneous detection of malaria and dengue |
Claudio Parolo |
Institut de Salut Global de Barcelona (ISGlobal) |
Consortium |
FURV-Fundació Universitat Rovira i Virgili |
STAGE 1 |
Diagnostics |
50,000,00 |
CI24-10670 |
Validation of a new methodology and biomarkers for predicting relapse in endometrial cancer patients |
Maria J. Macias |
Fundació Institut de Recerca Biomèdica (IRB Barcelona) |
Individual |
N/A |
STAGE 1 |
Diagnostics |
50,000,00 |
CI24-10681 |
Leveraging Genomics and AI for Non-Invasive Detection of Endometrial Cancer, a Urine Sample Solution |
Laura Costas |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Individual |
N/A |
STAGE 1 |
Diagnostics |
50,000,00 |
CI24-10743 |
Artificial Intelligence system for predicting embolisms in infective endocarditis |
J. Alberto San Román |
Hospital Clínico Universitario de Valladolid |
Individual |
N/A |
STAGE 1 |
Diagnostics |
50,000,00 |
CI24-10063 |
Biomimetic Bacterial NanoCellulose medical device with gradient porosity for osteochondral repair |
Miguel Gama |
Universidade do Minho |
Consortium |
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação; Universidade de Trás-os-Montes e Alto Douro |
STAGE 1 |
Medical Devices |
50,000,00 |
CI24-10305 |
Focused ultrasound therapy for repairing spinal cord in people with Multiple Sclerosis (MS) |
Pablo Villoslada |
Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) |
Individual |
N/A |
STAGE 1 |
Medical Devices |
50,000,00 |
CI24-10293 |
Hereditary Diffuse Gastric Cancer origins disclosed by organoid driven organ-on-chip technology |
Daniel A. Ferreira |
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação |
Individual |
N/A |
STAGE 1 |
Diagnostics |
49,000,00 |
CI24-20222 |
NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease |
Julia Lorenzo |
Universitat Autònoma de Barcelona (UAB) |
Consortium |
Fundación de la Comunidad Valenciana Centro de Investigación Príncipe Felipe; Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) |
STAGE 2 |
Therapeutics |
150,000,00 |
CI24-20449 |
Cecilia Rodrigues |
FARM-ID - Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento |
Individual |
N/A |
STAGE 2 |
Therapeutics |
150,000,00 |
|
CI24-20467 |
Development of a microRNA-regulated cell death-inducing gene therapy (miRGT) for cancer |
Ana Rita Fragoso |
Instituto de Medicina Molecular |
Individual |
N/A |
STAGE 2 |
Therapeutics |
149,032,50 |
CI24-20581 |
Towards an effective and safe therapy for hormonal-deficiency osteoporosis based on klotho protein |
Joan Roig |
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) |
Consortium |
Universitat Autònoma de Barcelona (UAB) |
STAGE 2 |
Therapeutics |
145,850,00 |
CI24-20693 |
Targeting CDK16-18 as a novel strategy against aggressive cancers |
Marcos Malumbres |
Fundació privada Institut Investigació Oncologica Vall d'Hebron (VHIO) |
Individual |
N/A |
STAGE 2 |
Therapeutics |
150,000,00 |
CI24-20107 |
A medical brain computer interface device to improve social cognition in autism spectrum disorder |
Miguel Castelo-Branco |
Universidade de Coimbra |
Individual |
N/A |
STAGE 2 |
Medical Devices |
148,980,19 |
CI24-20130 |
Artificial intelligence collaborative robot for patient-specific laser treatment of vascular lesions |
Bruno Oliveira |
Instituto Politécnico do Cávado e do Ave |
Consortium |
University of Southern Denmark (Dinamarca) |
STAGE 2 |
Medical Devices |
150,000,00 |
CI24-20329 |
Famba: international surveillance and data analytics platform for prevention of emerging pandemics |
José Muñoz |
Institut de Salut Global de Barcelona (ISGlobal) |
Consortium |
Institute of Tropical Medicine, Antwerp (Belgium); LMU Klinikum (Germany); IRCCS Ospedale Sacro-Cuore Don Calabria (Italy) |
STAGE 2 |
Digital Health |
149,930,00 |
CI24-20447 |
CRISPR-Cas Endonuclease Chain Reaction: a revolution in point-of-care genetic testing |
Felipe Cortés |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III |
Individual |
N/A |
STAGE 2 |
Diagnostics |
150,000,00 |
CI24-20499 |
NeurAntigen: A Human Neural Method for the Diagnosis of Autoimmune Encephalitis |
Eugenia Martínez Hernández |
Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer |
Consortium |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
STAGE 2 |
Diagnostics |
150,000,00 |
CI24-20039 |
Salvio Suárez |
Fundació Institut Català de Nanociència i Nanotecnologia |
Individual |
N/A |
STAGE 2 |
Medical Devices |
150,000,00 |
|
CI24-30620 |
Heptammune: a first-in-class biologic immunomodulator against autoimmune inflammatory bowel disease |
Josep M. Aran |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Individual |
N/A |
STAGE 3 |
Therapeutics |
500,000,00 |
CI24-30165 |
Víctor Rodriguez |
Consejo Superior de Investigaciones Científicas (CSIC) |
Individual |
N/A |
STAGE 3 |
Medical Devices |
499,000,00 |
Projetos selecionados CaixaImpulse 2023
Projetos selecionados CaixaImpulse 2023
CODE |
TITLE |
PROJECT LEADER |
CENTRE |
MODALITY |
PARTNER INSTITUTIONS |
STAGE |
BUSINESS AREA |
BUDGET (€) |
|---|---|---|---|---|---|---|---|---|
CI23-10022 |
Smart dendritic contrast agent for accurate stroke diagnosis by computed tomography |
Victoria Leiro |
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação |
Individual |
N/A |
STAGE |
Diagnostics |
49,996(*) |
CI23-10074 |
Pre-clinical development of a DNA vaccine to elicit immunity against K. pneumoniae virulence factors |
Mireia López |
Universitat de Girona |
Individual |
N/A |
STAGE |
Therapeutics |
50,000 |
CI23-10079 |
Overcoming resistance to virotherapy for pediatric brain tumors |
Marta Alonso |
Fundación para la Investigación Médica Aplicada (FIMA/CIMA) |
Individual |
N/A |
STAGE |
Therapeutics |
50,000 |
CI23-10134 |
Nano-coatings for prosthetics based on microbial phenazines conjugated with silver nanostars |
Pedro Soares |
Instituto de Medicina Molecular |
Individual |
N/A |
STAGE |
Medical Devices |
50,000 |
CI23-10157 |
Revolutionizing Electronic Skin: Biobatteries Powered |
Ana Pina |
Universidade Nova de Lisboa |
Consortium |
Materials Research UCIBIO - Applied Molecular Biosciences Instituto de Tecnologia - Química e Instituto Gulbenkian de Ciência |
STAGE |
Medical Devices |
49,000 |
CI23-10184 |
Luisa Lopes |
Instituto de Medicina Molecular |
Individual |
N/A |
STAGE |
Therapeutics |
50,000 |
|
CI23-10272 |
A versatile and stress-resistant biocatalyst nanoplatform for pathogen detection |
Mónica Serrano |
Universidade Nova de Lisboa |
Individual |
N/A |
STAGE |
Diagnostics |
49,000 |
CI23-10330 |
A novel liquid biopsy approach for early breast cancer detection in lactating women |
Ana Vivancos |
Fundació privada Institut Investigació Oncologica Vall Hebron (VHIO) |
Individual |
N/A |
STAGE |
Diagnostics |
50,000 |
CI23-10376 |
Preliminar demonstration and valorization of therapeutic rewiring of (partially) severed spinal cord |
Maurizio Prato |
Asociación Centro de Investigación Cooperativa en Biomateriales |
Individual |
N/A |
STAGE |
Medical Devices |
50,000 |
CI23-10380 |
New subset of neutrophils as a biomarker and a therapeutic target for metastatic breast cancer |
Maria de Guadalupe Gonçalves |
Universidade Nova de Lisboa |
Individual |
N/A |
STAGE |
Therapeutics |
49,000(*) |
CI23-10420 |
Isabelle Vernos |
Centre de Regulació Genòmica (CRG) |
Individual |
N/A |
STAGE |
Therapeutics |
50,000 |
|
CI23-10434 |
RACE Plus: AI-driven application to allow pre-hospital diagnosis and management of stroke patients |
Natalia Pérez de la Ossa |
Fundació Institut d’Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) |
Individual |
N/A |
STAGE |
Digital Health |
50,000 |
CI23-10562 |
Developing a new therapeutic approach to overcome resistance to checkpoint inhibitors |
Rodrigo Toledo |
Fundació privada Institut Investigació Oncologica Vall Hebron (VHIO) |
Individual |
N/A |
STAGE |
Therapeutics |
48,700 |
CI23-20154 |
New Biomarker for NAFLD and NASH Development and Progression |
David Martinez |
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) |
Individual |
N/A |
STAGE |
Diagnostics |
50,000 |
CI23-20369 |
CarboSign7 for pancreatic cancer diagnosis: Biosampling optimization |
Oscar Pozo |
Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) |
Consortium |
Hospital del Mar - Parc de Salut MAR |
STAGE |
Diagnostics |
50,000 |
CI23-20043 |
Novel gut-restricted first-in-class therapy for Inflammatory Bowel Disease |
Isabel Huber |
Fundació Institut d'Investigació Sanitària Pere Virgili |
Individual |
|
STAGE |
Therapeutics |
150,000 |
CI23-20067 |
Novel far-red/NIR-activatable PDT agents for combating hypoxic tumors |
Vicente Marchán |
Universitat de Barcelona |
Individual |
N/A |
STAGE |
Therapeutics |
150,000 |
CI23-20148 |
Arteriovenous Fistula for Dialysis: Machine Learning based models for failure and Cardiac events |
José Ibeas |
Fundació Institut d'Investigació i Innovació Parc Taulí (I3PT) |
Individual |
N/A |
STAGE |
Digital Health |
150,000 |
CI23-20210 |
BlaDimiR, non-invasive urine-based diagnostic and therapy response predictor for bladder cancer |
Marta Dueñas |
Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre |
Individual |
N/A |
STAGE |
Diagnostics |
143,000 |
CI23-20216 |
Judith Guasch |
Consejo Superior de Investigaciones Científicas (CSIC) |
Individual |
N/A |
STAGE |
Medical Devices |
150,000 |
|
CI23-20229 |
Humanized Wnt-11 antibodies for cancer therapy: further validation and asset development |
Robert Kypta |
Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE |
Individual |
N/A |
STAGE |
Therapeutics |
150,000 |
CI23-20433 |
Microbiome-associated biomarkers for improved anal cancer prevention |
Sergio Serrano-Villar |
Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal |
Consortium |
Instituto de Catálisis y Petroleoquímica (ICP), CSIC Marie Curie, 2 – 28049 Madrid, Spain |
STAGE |
Diagnostics |
135,261 |
CI23-20487 |
Proof of concept for development of an ATMP based on modified pericytes for glioblastoma treatment |
Rut Valdor |
Universidad de Murcia |
Individual |
|
STAGE |
Therapeutics |
150,000 |
CI23-20514 |
Duacept, a novel bi-specific fusion protein to prevent transplant rejection |
Oriol Bestard |
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) |
Individual |
N/A |
STAGE |
Therapeutics |
148,500 |
CI23-20559 |
Pilar Coy |
Universidad de Murcia |
Individual |
N/A |
STAGE |
Medical Devices |
149,500 |
|
CI23-30155 |
Maria Luz Martinez |
Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE |
Individual |
N/A |
STAGE |
Therapeutics |
150,000 |
|
CI23-30260 |
MICROSCREEN_CRC: Microbial biomarker test for early diagnosis of colorectal cancer (MiCRC) |
Olfat Khannous |
Fundació Institut de Recerca Biomèdica (IRB Barcelona) |
Individual |
N/A |
STAGE |
Diagnostics |
150,000 |
CI23-30015 |
FIBROKIT: First IVD-based non-invasive monitoring of kidney fibrosis |
Francesc E. Borras |
Fundació Institut d’Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) |
Individual |
N/A |
STAGE |
Diagnostics |
300,000 |
CI23-30316 |
LCOR mRNA NanoTherapies - A paradigm shift in immunotherapies against cancer |
Toni Celià-Terrassa |
Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) |
Individual |
N/A |
STAGE |
Therapeutics |
500,000 |
(*) Project cofunded by the Fundação para a Ciência e a Tecnologia (FCT)